Blocking inflammation on the way: Rationale for CXCR2 antagonists for the treatment of COVID-19

Blocking inflammation on the way: Rationale for CXCR2 antagonists for the treatment of COVID-19

An exacerbated and unbalanced immune response may account for the severity of COVID-19, the disease caused by the novel severe acute respiratory syndrome (SARS) coronavirus 2, SARS-CoV-2. In this Viewpoint, we summarize recent evidence for the role of neutrophils in the pathogenesis of COVID-19 and...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:The Journal of experimental medicine 2020-09, Vol.217 (9)
Hauptverfasser: Koenig, Lars M, Boehmer, Daniel F R, Metzger, Philipp, Schnurr, Max, Endres, Stefan, Rothenfusser, Simon
Format: Artikel
Sprache:eng
Schlagworte:
Betacoronavirus
Coronavirus Infections - epidemiology
COVID-19
Humans
Infectious Disease and Host Defense
Inflammation
Innate Immunity and Inflammation
Pandemics
Pneumonia, Viral
SARS-CoV-2
Viewpoint
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:An exacerbated and unbalanced immune response may account for the severity of COVID-19, the disease caused by the novel severe acute respiratory syndrome (SARS) coronavirus 2, SARS-CoV-2. In this Viewpoint, we summarize recent evidence for the role of neutrophils in the pathogenesis of COVID-19 and propose CXCR2 inhibition as a promising treatment option to block neutrophil recruitment and activation.
ISSN:0022-1007
1540-9538
DOI:10.1084/jem.20201342